CX Institutional’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $670K | Sell |
27,825
-11,707
| -30% | -$306K | 0.02% | 399 |
|
|
2026
Q1 | $1.11M | Buy |
39,532
+2,241
| +6% | +$59.7K | 0.03% | 324 |
|
|
2025
Q4 | $929K | Buy |
37,291
+1,418
| +4% | +$35.8K | 0.03% | 301 |
|
|
2025
Q3 | $914K | Sell |
35,873
-11,159
| -24% | -$275K | 0.03% | 315 |
|
|
2025
Q2 | $1.14M | Buy |
47,032
+15,797
| +51% | +$368K | 0.04% | 251 |
|
|
2025
Q1 | $791K | Sell |
31,235
-19,155
| -38% | -$501K | 0.03% | 307 |
|
|
2024
Q4 | $1.34M | Buy |
50,390
+4,183
| +9% | +$113K | 0.05% | 223 |
|
|
2024
Q3 | $1.34M | Buy |
46,207
+20,552
| +80% | +$600K | 0.06% | 243 |
|
|
2024
Q2 | $718K | Sell |
25,655
-24,403
| -49% | -$672K | 0.03% | 325 |
|
|
2024
Q1 | $1.39M | Sell |
50,058
-59,800
| -54% | -$1.66M | 0.07% | 231 |
|
|
2023
Q4 | $3.16M | Buy |
109,858
+5,627
| +5% | +$170K | 0.17% | 163 |
|
|
2023
Q3 | $3.46M | Buy |
104,231
+56,661
| +119% | +$2M | 0.19% | 134 |
|
|
2023
Q2 | $1.74M | Sell |
47,570
-6,940
| -13% | -$270K | 0.09% | 222 |
|
|
2023
Q1 | $2.25M | Sell |
54,510
-200
| -0.4% | -$8.64K | 0.12% | 207 |
|
|
2022
Q4 | $2.8M | Buy |
54,710
+10,058
| +23% | +$482K | 0.17% | 165 |
|
|
2022
Q3 | $1.95M | Sell |
44,652
-56,135
| -56% | -$2.73M | 0.14% | 187 |
|
|
2022
Q2 | $5.28M | Buy |
100,787
+14,197
| +16% | +$723K | 0.4% | 57 |
|
|
2022
Q1 | $4.48M | Sell |
86,590
-20,258
| -19% | -$1.05M | 0.36% | 76 |
|
|
2021
Q4 | $6.31M | Buy |
106,848
+72,378
| +210% | +$3.59M | 0.5% | 52 |
|
|
2021
Q3 | $1.48M | Sell |
34,470
-31,788
| -48% | -$1.41M | 0.12% | 177 |
|
|
2021
Q2 | $2.6M | Buy |
66,258
+3,068
| +5% | +$119K | 0.21% | 114 |
|
|
2021
Q1 | $2.29M | Sell |
63,190
-33,678
| -35% | -$1.2M | 0.2% | 123 |
|
|
2020
Q4 | $3.57M | Sell |
96,868
-19,190
| -17% | -$704K | 0.34% | 73 |
|
|
2020
Q3 | $4.04M | Buy |
116,058
+87,814
| +311% | +$3.08M | 0.44% | 61 |
|
|
2020
Q2 | $876K | Sell |
28,244
-405
| -1% | -$13.8K | 0.12% | 155 |
|
|
2020
Q1 | $887K | Buy |
28,649
+1,218
| +4% | +$41.5K | 0.14% | 140 |
|
|
2019
Q4 | $1.02M | Sell |
27,431
-115
| -0.4% | -$4.1K | 0.18% | 110 |
|
|
2019
Q3 | $939K | Buy |
27,546
+134
| +0.5% | +$4.87K | 0.15% | 134 |
|
|
2019
Q2 | $1.13M | Sell |
27,412
-3,121
| -10% | -$124K | 0.18% | 120 |
|
|
2019
Q1 | $1.23M | Buy |
30,533
+5,498
| +22% | +$220K | 0.22% | 117 |
|
|
2018
Q4 | $1.04M | Sell |
25,035
-14,440
| -37% | -$599K | 0.22% | 85 |
|
|
2018
Q3 | $1.65M | Buy |
39,475
+1,471
| +4% | +$56.6K | 0.55% | 52 |
|
|
2018
Q2 | $1.31M | Buy |
+38,004
| New | +$1.3M | 0.48% | 61 |
|
Other funds holding PFE
CX Institutional's PFE Position: Q2 2026 in Review
CX Institutional reduced its Pfizer (PFE) stake by 30% in Q2 2026, selling an estimated $306K and leaving 27,825 shares worth $670K. The position accounts for 0.02% of the portfolio, ranked #399.
CX Institutional first reported a position in PFE in Q2 2018 and has held it in 33 quarters since. The position peaked at $6.31M in Q4 2021. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- CX Institutional held 27,825 shares of Pfizer worth $670K as of Q2 2026.
- CX Institutional sold 11,707 Pfizer shares in Q2 2026, an estimated $306K.
- Pfizer made up 0.02% of CX Institutional's portfolio in Q2 2026, its #399 holding.
- CX Institutional first reported a position in Pfizer in Q2 2018 and has held it in 33 quarters since.
- CX Institutional's Pfizer position peaked at $6.31M in Q4 2021.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.